, 2022-07-02 20:22:08,
Exact Sciences Co. (NASDAQ:EXAS – Get Rating) Director Katherine S. Zanotti sold 1,086 shares of the firm’s stock in a transaction on Thursday, June 30th. The shares were sold at an average price of $40.13, for a total transaction of $43,581.18. Following the transaction, the director now owns 60,318 shares in the company, valued at approximately $2,420,561.34. The transaction was disclosed in a document filed with the SEC, which is available at this link.
NASDAQ EXAS traded up $1.74 during midday trading on Friday, hitting $41.13. The company had a trading volume of 1,460,043 shares, compared to its average volume of 2,158,426. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.67. The stock has a market cap of $7.24 billion, a price-to-earnings ratio of -9.52 and a beta of 1.24. The firm has a fifty day simple moving average of $48.44 and a two-hundred day simple moving average of $64.44. Exact Sciences Co. has a fifty-two week low of $35.34 and a fifty-two week high of $125.00.
Exact Sciences (NASDAQ:EXAS – Get Rating) last posted its quarterly earnings results on Tuesday, April 26th. The medical research company reported ($1.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.08. The company had revenue of $486.57 million for the quarter, compared to analyst estimates of $461.86 million. Exact Sciences had a negative net margin of 40.26% and a negative return on equity of 21.82%. During the same period last year, the business posted ($0.18) EPS. As a group, equities analysts predict that Exact Sciences Co. will post -4.25 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business….
To read the original article, go to Click here